GB201720279D0 - Anticancer compounds - Google Patents

Anticancer compounds

Info

Publication number
GB201720279D0
GB201720279D0 GBGB1720279.7A GB201720279A GB201720279D0 GB 201720279 D0 GB201720279 D0 GB 201720279D0 GB 201720279 A GB201720279 A GB 201720279A GB 201720279 D0 GB201720279 D0 GB 201720279D0
Authority
GB
United Kingdom
Prior art keywords
anticancer compounds
anticancer
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1720279.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucana PLC
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Priority to GBGB1720279.7A priority Critical patent/GB201720279D0/en
Publication of GB201720279D0 publication Critical patent/GB201720279D0/en
Priority to US16/769,635 priority patent/US11560400B2/en
Priority to EA202091218A priority patent/EA202091218A1/ru
Priority to JP2020530585A priority patent/JP7268819B2/ja
Priority to BR112020011221-6A priority patent/BR112020011221A2/pt
Priority to MA051006A priority patent/MA51006A/fr
Priority to SG11202004342TA priority patent/SG11202004342TA/en
Priority to PL18819340T priority patent/PL3720864T3/pl
Priority to MA051007A priority patent/MA51007A/fr
Priority to PCT/GB2018/053525 priority patent/WO2019110991A1/en
Priority to CA3082269A priority patent/CA3082269A1/en
Priority to KR1020207016514A priority patent/KR20200092980A/ko
Priority to HRP20220451TT priority patent/HRP20220451T1/hr
Priority to ES18819340T priority patent/ES2910165T3/es
Priority to PT188193403T priority patent/PT3720864T/pt
Priority to EP18819340.3A priority patent/EP3720864B1/en
Priority to CN201880078576.6A priority patent/CN111527098A/zh
Priority to AU2018379713A priority patent/AU2018379713A1/en
Priority to DK18819340.3T priority patent/DK3720864T3/da
Priority to EP21218125.9A priority patent/EP4043471A1/en
Priority to MX2020005850A priority patent/MX2020005850A/es
Priority to IL274808A priority patent/IL274808B2/en
Priority to PH12020550728A priority patent/PH12020550728A1/en
Priority to CL2020001479A priority patent/CL2020001479A1/es
Priority to US18/083,089 priority patent/US20230192750A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
GBGB1720279.7A 2017-12-05 2017-12-05 Anticancer compounds Ceased GB201720279D0 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GBGB1720279.7A GB201720279D0 (en) 2017-12-05 2017-12-05 Anticancer compounds
MX2020005850A MX2020005850A (es) 2017-12-05 2018-12-05 Sales de fosforamidato de difosfato de nucleosidos como compuestos anticancerigenos.
HRP20220451TT HRP20220451T1 (hr) 2017-12-05 2018-12-05 Soli difosfatnog fosforamidata nukleozida kao antikancerogeni spojevi
PT188193403T PT3720864T (pt) 2017-12-05 2018-12-05 Sais de fosforamidato de difosfato de nucleósidos como compostos anticancerosos
JP2020530585A JP7268819B2 (ja) 2017-12-05 2018-12-05 抗癌剤化合物としてのヌクレオシドのジホスフェートホスホルアミデートの塩
BR112020011221-6A BR112020011221A2 (pt) 2017-12-05 2018-12-05 compostos de difosfato fosforamidato de nucleosídeos, seu uso no tratamento de câncer e composições farmacêuticas compreendendo os mesmos
MA051006A MA51006A (fr) 2017-12-05 2018-12-05 Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux
SG11202004342TA SG11202004342TA (en) 2017-12-05 2018-12-05 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
PL18819340T PL3720864T3 (pl) 2017-12-05 2018-12-05 Sole fosforoamidatu difosforanowego nukleozydów jako związki przeciwnowotworowe
MA051007A MA51007A (fr) 2017-12-05 2018-12-05 Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux
PCT/GB2018/053525 WO2019110991A1 (en) 2017-12-05 2018-12-05 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
CA3082269A CA3082269A1 (en) 2017-12-05 2018-12-05 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
KR1020207016514A KR20200092980A (ko) 2017-12-05 2018-12-05 뉴클레오시드의 디포스페이트 포스포아미데이트의 염 항암 화합물
US16/769,635 US11560400B2 (en) 2017-12-05 2018-12-05 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
ES18819340T ES2910165T3 (es) 2017-12-05 2018-12-05 Sales de fosforamidato de difosfato de nucleósidos como compuestos contra el cáncer
EA202091218A EA202091218A1 (ru) 2017-12-05 2018-12-05 Соли дифосфатфосфорамидата нуклеозидов в качестве противораковых соединений
EP18819340.3A EP3720864B1 (en) 2017-12-05 2018-12-05 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
CN201880078576.6A CN111527098A (zh) 2017-12-05 2018-12-05 作为抗癌化合物的核苷的二磷酸氨基磷酸酯的盐
AU2018379713A AU2018379713A1 (en) 2017-12-05 2018-12-05 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
DK18819340.3T DK3720864T3 (da) 2017-12-05 2018-12-05 Salte af diphosphatphosphoramidat af nukleosider som anticancerforbindelser
EP21218125.9A EP4043471A1 (en) 2017-12-05 2018-12-05 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
IL274808A IL274808B2 (en) 2017-12-05 2020-05-20 Phosphoramidate diphosphate salts of nucleosides as anticancer compounds
PH12020550728A PH12020550728A1 (en) 2017-12-05 2020-05-28 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
CL2020001479A CL2020001479A1 (es) 2017-12-05 2020-06-03 Sales de fosforamitato de difosfato de nucleosidos como compuestos contra el cáncer.
US18/083,089 US20230192750A1 (en) 2017-12-05 2022-12-16 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720279.7A GB201720279D0 (en) 2017-12-05 2017-12-05 Anticancer compounds

Publications (1)

Publication Number Publication Date
GB201720279D0 true GB201720279D0 (en) 2018-01-17

Family

ID=60950385

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1720279.7A Ceased GB201720279D0 (en) 2017-12-05 2017-12-05 Anticancer compounds

Country Status (22)

Country Link
US (2) US11560400B2 (https=)
EP (2) EP3720864B1 (https=)
JP (1) JP7268819B2 (https=)
KR (1) KR20200092980A (https=)
CN (1) CN111527098A (https=)
AU (1) AU2018379713A1 (https=)
BR (1) BR112020011221A2 (https=)
CA (1) CA3082269A1 (https=)
CL (1) CL2020001479A1 (https=)
DK (1) DK3720864T3 (https=)
EA (1) EA202091218A1 (https=)
ES (1) ES2910165T3 (https=)
GB (1) GB201720279D0 (https=)
HR (1) HRP20220451T1 (https=)
IL (1) IL274808B2 (https=)
MA (2) MA51006A (https=)
MX (1) MX2020005850A (https=)
PH (1) PH12020550728A1 (https=)
PL (1) PL3720864T3 (https=)
PT (1) PT3720864T (https=)
SG (1) SG11202004342TA (https=)
WO (1) WO2019110991A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291927A (en) 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
CN116768949B (zh) * 2022-07-12 2026-03-03 南京工业大学 一种基于3’-脱氧腺苷经化学修饰改性的具有抗癌效应的化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2010135520A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
HUE029022T2 (en) 2011-03-01 2017-02-28 Nucana Biomed Ltd Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
WO2014124430A1 (en) * 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
IL291927A (en) 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
SG10202013032YA (en) * 2014-12-15 2021-02-25 Univ Emory Phosphoramidates for the treatment of hepatitis b virus
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
WO2017106710A1 (en) 2015-12-17 2017-06-22 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
US20190085013A1 (en) 2016-03-07 2019-03-21 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds

Also Published As

Publication number Publication date
JP7268819B2 (ja) 2023-05-08
CL2020001479A1 (es) 2020-12-18
ES2910165T3 (es) 2022-05-11
JP2021505578A (ja) 2021-02-18
US20230192750A1 (en) 2023-06-22
CN111527098A (zh) 2020-08-11
PL3720864T3 (pl) 2022-05-02
CA3082269A1 (en) 2019-06-13
HRP20220451T1 (hr) 2022-05-27
PT3720864T (pt) 2022-04-06
IL274808A (en) 2020-07-30
MA51007A (fr) 2020-10-14
MX2020005850A (es) 2020-09-07
EA202091218A1 (ru) 2020-09-14
KR20200092980A (ko) 2020-08-04
PH12020550728A1 (en) 2021-02-15
IL274808B1 (en) 2023-04-01
IL274808B2 (en) 2023-08-01
US11560400B2 (en) 2023-01-24
EP4043471A1 (en) 2022-08-17
DK3720864T3 (da) 2022-04-11
AU2018379713A1 (en) 2020-07-23
WO2019110991A1 (en) 2019-06-13
EP3720864A1 (en) 2020-10-14
MA51006A (fr) 2020-10-14
SG11202004342TA (en) 2020-06-29
BR112020011221A2 (pt) 2020-11-17
US20210171566A1 (en) 2021-06-10
EP3720864B1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
ZA202002898B (en) Anticancer agents
GB201708456D0 (en) Senolytic compounds
GB201700814D0 (en) Compounds
GB201704327D0 (en) Compounds
GB201715342D0 (en) Compounds
GB201704325D0 (en) Compounds
GB201713962D0 (en) Compounds
ZA202006147B (en) Anticancer compounds
GB201707938D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201720279D0 (en) Anticancer compounds
GB201707856D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
SG11202105992SA (en) Anticancer compounds
HK40018989A (en) Anticancer compounds
GB201716352D0 (en) Compounds
GB201716374D0 (en) Compounds
GB201713319D0 (en) Compounds
GB201713318D0 (en) Compounds
GB201711982D0 (en) Compounds
GB201709642D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)